Book Text

REFERENCES

901. Sugai K, Sugai Y: Epidural anesthesia for a patient with Charcot-Marie-Tooth disease, bronchial asthma and hypothyroidism [in Japanese]. Masui 38:688–691, 1989.

902. Scull T, Weeks S: Epidural analgesia for labour in a patient with Charcot-Marie-Tooth disease. Can J Anaesth 43:1150–1152, 1996.

903. Emery AE: The muscular dystrophies. Lancet 359:687–695, 2002.

904. Hoffman EP, Brown RH Jr, Kunkel LM: Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51:919–928, 1987.

905. Hoffman EP, Fischbeck KH, Brown RH, et al: Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med 318:1363–1368, 1988.

906. Bione S, Maestrini E, Rivella S, et al: Identification of a novel X-linked gene responsible for Emergy-Dreifuss muscular dystrophy. Nat Genet 8:323–327, 1994.

907. Fenichel GM, Sul YC, Kilroy AW, et al: An autosomal-dominant dystrophy with humeropelvic distribution and cardiomyopathy. Neurology 32:1399–1401, 1982.

908. Moreira ES, Wiltshire TJ, Faulkner G, et al: Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nat Genet 24:163–166, 2000.

909. Naom I, D'Alessandro M, Sewry CA, et al: Mutations in the laminin alpha2-chain gene in two children with early-onset muscular dystrophy. Brain 123:31–41, 2000.

910. Saito Y, Mizuguchi M, Oka A, et al: Fukutin protein is expressed in neurons of the normal developing human brain but is reduced in Fukuyama-type congenital muscular dystrophy brain. Ann Neurol 47:756–764, 2000.

911. Mayer U, Saher G, Fassler R, et al: Absence of integrin alpha 7 causes a novel form of muscular dystrophy. Nat Genet 17:318–323, 1997.

912. Orrell RW, Tawil R, Forrester J, et al: Definitive molecular diagnosis of facioscapulohumeral dystrophy. Neurology 52:1822–1826, 1999.

913. Brook JD, McCurrach ME, Harley HG, et al: Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 68:799–808, 1992.

914. Ranum LP, Rasmussen PF, Benzow KA, et al: Genetic mapping of a second myotonic dystrophy locus. Nat Genet 19:196–198, 1998.

915. Durbeej M, Campbell KP: Muscular dystrophies involving the dystrophin-glycoprotein complex: An overview of current mouse models. Curr Opin Genet Dev 12:349–361, 2002.

916. Petrof BJ, Shrager JB, Stedman HH, et al: Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 90:3710–3714, 1993.

917. Pasternak C, Wong S, Elson EL: Mechanical function of dystrophin in muscle cells. J Cell Biol 128:355–361, 1995.

918. Coral-Vazquez R, Cohn RD, Moore SA, et al: Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: A novel mechanism for cardiomyopathy and muscular dystrophy. Cell 98:465–474, 1999.

919. Stamler JS, Meissner G: Physiology of nitric oxide in skeletal muscle. Physiol Rev 81:209–237, 2001.

920. Crosbie RH: NO vascular control in Duchenne muscular dystrophy. Nat Med 7:27–29, 2001.

921. Emery AE: The muscular dystrophies. BMJ 317:991–995, 1998.

922. Roland EH: Muscular dystrophy. Pediatr Rev 21:233–237, 2000.

923. Blake DJ, Kroger S: The neurobiology of Duchenne muscular dystrophy: Learning lessons from muscle? Trends Neurosci 23:92–99, 2000.

924. Koenig M, Hoffman EP, Bertelson CJ, et al: Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50:509–517, 1987.

925. Brown RH Jr: Dystrophin-associated proteins and the muscular dystrophies. Annu Rev Med 48:457–466, 1997.

926. Fukuyama Y, Osawa M, Suzuki H: Congenital progressive muscular dystrophy of the Fukuyama type—clinical, genetic and pathological considerations. Brain Dev 3:1–29, 1981.

927. Ishii H, Hayashi YK, Nonaka I, et al: Electron microscopic examination of basal lamina in Fukuyama congenital muscular dystrophy. Neuromuscul Disord 7:191–197, 1997.

568

928. Moll J, Barzaghi P, Lin S, et al: An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature 413:302–307, 2001.

929. Gussoni E, Soneoka Y, Strickland CD, et al: Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 401:390–394, 1999.

930. Emery AE, Dreifuss FE: Unusual type of benign X-linked muscular dystrophy. J Neurol Neurosurg Psychiatry 29:338–342, 1966.

931. Emery AE: Population frequencies of inherited neuromuscular diseases—a world survey. Neuromuscul Disord 1:19–29, 1991.

932. Aslanidis C, Jansen G, Amemiya C, et al: Cloning of the essential myotonic dystrophy region and mapping of the putative defect. Nature 355:548–551, 1992.

933. Shimokawa M, Ishiura S, Kameda N, et al: Novel isoform of myotonin protein kinase: Gene product of myotonic dystrophy is localized in the sarcoplasmic reticulum of skeletal muscle. Am J Pathol 150:1285–1295, 1997.

934. Damiani E, Angelini C, Pelosi M, et al: Skeletal muscle sarcoplasmic reticulum phenotype in myotonic dystrophy. Neuromuscul Disord 6:33–47, 1996.

935. Harper PS: Myotonic Dystrophy, 3rd ed. London, WB Saunders, 2001.

936. Krivickas LS, Ansved T, Suh D, et al: Contractile properties of single muscle fibers in myotonic dystrophy. Muscle Nerve 23:529–537, 2000.

937. Koltgen D, Franke C: The coexistence of embryonic and adult acetylcholine receptors in sarcolemma of mdx dystrophic mouse muscle: An effect of regeneration or muscular dystrophy? Neurosci Lett 173:79–82, 1994.

938. Brownell AK, Paasuke RT, Elash A, et al: Malignant hyperthermia in Duchenne muscular dystrophy. Anesthesiology 58:180–182, 1983.

939. Ohkoshi N, Yoshizawa T, Mizusawa H, et al: Malignant hyperthermia in a patient with Becker muscular dystrophy: Dystrophin analysis and caffeine contracture study. Neuromuscul Disord 5:53–58, 1995.

940. Buzello W, Huttarsch H: Muscle relaxation in patients with Duchenne's muscular dystrophy. Use of vecuronium in two patients. Br J Anaesth 60:228–231, 1988.

941. Ririe DG, Shapiro F, Sethna NF: The response of patients with Duchenne's muscular dystrophy to neuromuscular blockade with vecuronium. Anesthesiology 88:351–354, 1998.

942. Uslu M, Mellinghoff H, Diefenbach C: Mivacurium for muscle relaxation in a child with Duchenne's muscular dystrophy. Anesth Analg 89:340–341, 1999.

943. Kaufman L: Dystrophia myotonica and succinylcholine [letter]. Anaesthesia 55:929, 2000.

944. Nightingale P, Healy TE, McGuinness K: Dystrophia myotonica and atracurium. A case report. Br J Anaesth 57:1131–1135, 1985.

945. Buzello W, Krieg N, Schlickewei A: Hazards of neostigmine in patients with neuromuscular disorders. Report of two cases. Br J Anaesth 54:529–534, 1982.

946. Sethna NF, Rockoff MA: Cardiac arrest following inhalation induction of anaesthesia in a child with Duchenne's muscular dystrophy. Can Anaesth Soc J 33:799–802, 1986.

947. Sethna NF, Rockoff MA, Worthen HM, et al: Anesthesia-related complications in children with Duchenne muscular dystrophy. Anesthesiology 68:462–465, 1988.

948. Obata R, Yasumi Y, Suzuki A, et al: Rhabdomyolysis in association with Duchenne's muscular dystrophy. Can J Anaesth 46:564–566, 1999.

949. Goresky GV, Cox RG: Inhalation anesthetics and Duchenne's muscular dystrophy. Can J Anaesth 46:525–528, 1999.

950. Bennun M, Goldstein B, Finkelstein Y, et al: Continuous propofol anaesthesia for patients with myotonic dystrophy. Br J Anaesth 85:407–409, 2000.

951. Mathieu J, Allard P, Gobeil G, et al: Anesthetic and surgical complications in 219 cases of myotonic dystrophy. Neurology 49:1646–1650, 1997.

952. Barohn RJ, Levine EJ, Olson JO, et al: Gastric hypomotility in Duchenne's muscular dystrophy. N Engl J Med 319:15–18, 1988.

953. Landrum AL, Eggers GW: Oculopharyngeal dystrophy: An approach to anesthetic management. Anesth Analg 75:1043–1045, 1992.

954. Staiano A, Del Giudice E, Romano A, et al: Upper gastrointestinal tract motility in children with progressive muscular dystrophy. J Pediatr 121:720–724, 1992.

955. Hopkins A, Wray S: The effect of pregnancy on dystrophia myotonica. Neurology 17:166–168, 1967.

956. Moxley RT 3rd, Kingston WJ, Minaker KL, et al: Insulin resistance and regulation of serum amino acid levels in myotonic dystrophy. Clin Sci (Lond) 71:429–436, 1986.

957. Ricker K: Myotonic dystrophy and proximal myotonic myopathy. J Neurol 246:334–338, 1999.

958. Bourke TD, Zuck D: Thiopentone in dystrophy myotonia. Br J Anaesth 29:35, 1957.

959. Speedy H: Exaggerated physiological responses to propofol in myotonic dystrophy. Br J Anaesth 64:110–112, 1990.

960. White DA, Smyth DG: Exaggerated physiological responses to propofol in myotonic dystrophy. Br J Anaesth 64:758–759, 1990.

961. Aldridge LM: Anaesthetic problems in myotonic dystrophy. A case report and review of the Aberdeen experience comprising 48 general anaesthetics in a further 16 patients. Br J Anaesth 57:1119–1130, 1985.

962. Shapiro F, Sethna N, Colan S, et al: Spinal fusion in Duchenne muscular dystrophy: A multidisciplinary approach. Muscle Nerve 15:604–614, 1992.

963. Aldwinckle RJ, Carr AS: The anesthetic management of a patient with Emery-Dreifuss muscular dystrophy for orthopedic surgery. Can J Anaesth 49:467–470, 2002.

964. Shiraishi M, Minami K, Kadaya T: A safe anesthetic method using caudal block and ketamine for the child with congenital myotonic dystrophy. Anesth Analg 94:233, 2002.

965. Noordeen MH, Haddad FS, Muntoni F, et al: Blood loss in Duchenne muscular dystrophy: Vascular smooth muscle dysfunction? J Pediatr Orthop B 8:212–215, 1999.

966. Forst J, Forst R, Leithe H, et al: Platelet function deficiency in Duchenne muscular dystrophy. Neuromuscul Disord 8:46–49, 1998.

967. Schaefer AM, Taylor RW, Turnbull DM: The mitochondrial genome and mitochondrial muscle disorders. Curr Opin Pharmacol 1:288–293, 2001.

968. Chinnery PF, Johnson MA, Wardell TM, et al: The epidemiology of pathogenic mitochondrial DNA mutations. Ann Neurol 48:188–193, 2000.

969. Collombet JM, Coutelle C: Towards gene therapy of mitochondrial disorders. Mol Med Today 4:31–38, 1998.

970. Chinnery PF, Howell N, Andrews RM, et al: Clinical mitochondrial genetics. J Med Genet 36:425–436, 1999.

971. Rifai Z, Welle S, Kamp C, et al: Ragged red fibers in normal aging and inflammatory myopathy. Ann Neurol 37:24–29, 1995.

972. Dalakas MC, Illa I, Pezeshkpour GH, et al: Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 322:1098–1105, 1990.

973. Clay AS, Behnia M, Brown KK: Mitochondrial disease: A pulmonary and critical-care medicine perspective. Chest 120:634–648, 2001.

974. Parke TJ, Stevens JE, Rice AS, et al: Metabolic acidosis and fatal myocardial failure after propofol infusion in children: Five case reports. BMJ 305:613–616, 1992.

975. Cray SH, Robinson BH, Cox PN: Lactic acidemia and bradyarrhythmia in a child sedated with propofol. Crit Care Med 26:2087–2092, 1998.

976. Stacpoole PW: Lactic acidosis. Endocrinol Metab Clin North Am 22:221–245, 1993.

977. Badr AE, Mychaskiw G 2nd, Eichhorn JH: Metabolic acidosis associated with a new formulation of propofol. Anesthesiology 94:536–538, 2001.

978. van den Ouweland JM, Lemkes HH, Ruitenbeek W, et al: Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet 1:368–371, 1992.

569

979. Carroll JE, Zwillich C, Weil JV, et al: Depressed ventilatory response in oculocraniosomatic neuromuscular disease. Neurology 26:140–146, 1976.

980. Cros D, Palliyath S, DiMauro S, et al: Respiratory failure revealing mitochondrial myopathy in adults. Chest 101:824–828, 1992.

981. Manni R, Piccolo G, Banfi P, et al: Respiratory patterns during sleep in mitochondrial myopathies with ophthalmoplegia. Eur Neurol 31:12–17, 1991.

982. DiMauro S, Bonilla E, Davidson M, et al: Mitochondria in neuromuscular disorders. Biochim Biophys Acta 1366:199–210, 1998.

983. Wang J, Wilhelmsson H, Graff C, et al: Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. Nat Genet 21:133–137, 1999.

984. Howell N: Human mitochondrial diseases: Answering questions and questioning answers. Int Rev Cytol 186:49–116, 1999.

985. D'Ambra MN, Dedrick D, Savarese JJ: Kearns-Sayer syndrome and pancuronium-succinylcholine-induced neuromuscular blockade. Anesthesiology 51:343–345, 1979.

986. Naguib M, el Dawlatly AA, Ashour M, et al: Sensitivity to mivacurium in a patient with mitochondrial myopathy. Anesthesiology 84:1506–1509, 1996.

987. Finsterer J, Stratil U, Bittner R, et al: Increased sensitivity to rocuronium and atracurium in mitochondrial myopathy. Can J Anaesth 45:781–784, 1998.

988. Lessell S, Kuwabara T, Feldman RG: Myopathy and succinylcholine sensitivity. Am J Ophthalmol 68:789–796, 1969.

989. Figarella-Branger D, Kozak-Ribbens G, Rodet L, et al: Pathological findings in 165 patients explored for malignant hyperthermia susceptibility. Neuromuscul Disord 3:553–556, 1993.

990. Etcharry-Bouyx F, Sangla I, Serratrice G: Chronic rhabdomyolysis disclosing mitochondriopathy and malignant hyperthermia susceptibility [in French]. Rev Neurol (Paris) 151:589–592, 1995.

991. Fricker RM, Raffelsberger T, Rauch-Shorny S, et al: Positive malignant hyperthermia susceptibility in vitro test in a patient with mitochondrial myopathy and myoadenylate deaminase deficiency. Anesthesiology 97:1635–1637, 2002.

992. Maslow A, Lisbon A: Anesthetic considerations in patients with mitochondrial dysfunction. Anesth Analg 76:884–886, 1993.

993. Rosaeg OP, Morrison S, MacLeod JP: Anaesthetic management of labour and delivery in the parturient with mitochondrial myopathy. Can J Anaesth 43:403–407, 1996.

994. Celesia GG: Disorders of membrane channels or channelopathies. Clin Neurophysiol 112:2–18, 2001.

995. Siegelbaum SA, Koester J: Ion channels. In Kandel ER, Scharrtz JH, Jessel TM (eds): Principles of Neural Science. New York, McGraw-Hill, 2000, pp 105–125.

996. Ashcroft FM: Ion Channels and Disease. London, Academic Press, 2000.

997. Jurkat-Rott K, Lerche H, Lehmann-Horn F: Skeletal muscle channelopathies. J Neurol 249:1493–1502, 2002.

998. Waxman SG: Transcriptional channelopathies: An emerging class of disorders. Nat Rev Neurosci 2:652–659, 2001.

999. Black JA, Dib-Hajj S, Baker D, et al: Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis. Proc Natl Acad Sci U S A 97:11598–11602, 2000.

1000. Koch MC, Steinmeyer K, Lorenz C, Ricker K, et al: The skeletal muscle chloride channel in dominant and recessive human myotonia. Science 257:797–800, 1992.

1001. George AL Jr, Crackower MA, Abdalla JA, et al: Molecular basis of Thomsen's disease (autosomal dominant myotonia congenita). Nat Genet 3:305–310, 1993.

1002. Fontaine B, Khurana TS, Hoffman EP, et al: Hyperkalemic periodic paralysis and the adult muscle sodium channel alpha-subunit gene. Science 250:1000–1002, 1990.

1003. Lerche H, Heine R, Pika U, et al: Human sodium channel myotonia: Slowed channel inactivation due to substitutions for a glycine within the III–IV linker. J Physiol (Lond) 470:13–22, 1993.

1004. Ricker K, Moxley RT 3rd, Heine R, et al: Myotonia fluctuans. A third type of muscle sodium channel disease. Arch Neurol 51:1095–1102, 1994.

1005. Fontaine B, Vale-Santos J, Jurkat-Rott K, et al: Mapping of the hypokalaemic periodic paralysis (HypoPP) locus to chromosome 1q31-32 in three European families. Nat Genet 6:267–272, 1994.

1006. Jurkat-Rott K, Mitrovic N, Hang C, et al: Voltage-sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current. Proc Natl Acad Sci U S A 97:9549–9554, 2000.

1007. Quane KA, Healy JM, Keating KE, et al: Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 5:51–55, 1993.

1008. Zhang Y, Chen HS, Khanna VK, et al: A mutation in the human ryanodine receptor gene associated with central core disease. Nat Genet 5:46–50, 1993.

1009. Sine SM, Ohno K, Bouzat C, et al: Mutation of the acetylcholine receptor alpha subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. Neuron 15:229–239, 1995.

1010. Hoffman EP: Voltage-gated ion channelopathies: Inherited disorders caused by abnormal sodium, chloride, and calcium regulation in skeletal muscle. Annu Rev Med 46:431–441, 1995.

1011. Cooper EC, Jan LY: Ion channel genes and human neurological disease: Recent progress, prospects, and challenges. Proc Natl Acad Sci U S A 96:4759–4766, 1999.

1012. Lehmann-Horn F, Jurkat-Rott K: Voltage-gated ion channels and hereditary disease. Physiol Rev 79:1317–1372, 1999.

1013. Kleopa KA, Barchi RL: Genetic disorders of neuromuscular ion channels. Muscle Nerve 26:299–325, 2002.

1014. Lehmann-Horn F, Jurkat-Rott K, Rudel R: Periodic paralysis: Understanding channelopathies. Curr Neurol Neurosci Rep 2:61–69, 2002.

1015. Rios E, Pizarro G: Voltage sensor of excitation-contraction coupling in skeletal muscle. Physiol Rev 71:849–908, 1991.

1016. Fill M, Copello JA: Ryanodine receptor calcium release channels. Physiol Rev 82:893–922, 2002.

1017. MacKrill JJ: Protein-Protein interactions in intracellular Ca²⁺ -release channel function. Biochem J 337 (Pt 3):345–361, 1999.

1018. Vincent A, Palace J, Hilton-Jones D: Myasthenia gravis. Lancet 357:2122–2128, 2001.

1019. Vincent A: Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2:797–804, 2002.

1020. Lindstrom JM: Acetylcholine receptors and myasthenia. Muscle Nerve 23:453–477, 2000.

1021. Drachman DB: Myasthenia gravis. N Engl J Med 330:1797–1810, 1994.

1022. Phillips WD, Vladeta D, Han H, et al: Rapsyn and agrin slow the metabolic degradation of the acetylcholine receptor. Mol Cell Neurosci 10:16–26, 1997.

1023. Tzartos SJ, Lindstrom JM: Monoclonal antibodies used to probe acetylcholine receptor structure: Localization of the main immunogenic region and detection of similarities between subunits. Proc Natl Acad Sci U S A 77:755–759, 1980.

1024. Lang TJ, Badea TC, Wade R, et al: Sublytic terminal complement attack on myotubes decreases the expression of mRNAs encoding muscle-specific proteins. J Neurochem 68:1581–1589, 1997.

1025. Lindstrom JM, Seybold ME, Lennon VA, et al: Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26:1054–1059, 1976.

1026. Whitney KD, McNamara JO: Autoimmunity and neurological disease: Antibody modulation of synaptic transmission. Annu Rev Neurosci 22:175–195, 1999.

570

1027. Vincent A, Newsom-Davis J: Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: Results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48:1246–1252, 1985.

1028. Hoch W, McConville J, Helms S, et al: Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365–368, 2001.

1029. Valenzuela DM, Stitt TN, DiStefano PS, et al: Receptor tyrosine kinase specific for the skeletal muscle lineage: Expression in embryonic muscle, at the neuromuscular junction, and after injury. Neuron 15:573–584, 1995.

1030. Vernino S, Adamski J, Kryzer TJ, et al: Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology 50:1806–1813, 1998.

1031. Hatton PD, Diehl JT, Daly BD, et al: Transsternal radical thymectomy for myasthenia gravis: A 15-year review. Ann Thorac Surg 47:838–840, 1989.

1032. Deitiker P, Ashizawa T, Atassi MZ: Antigen mimicry in autoimmune disease. Can immune responses to microbial antigens that mimic acetylcholine receptor act as initial triggers of myasthenia gravis? Hum Immunol 61:255–265, 2000.

1033. Woolf AL: Morphology of the myasthenic neuromuscular junction. Ann N Y Acad Sci 135:35–59, 1966.

1034. Plomp JJ, van Kempen GT, Molenaar PC: Adaptation of quantal content to decreased postsynaptic sensitivity at single endplates in alpha-bungarotoxin-treated rats. J Physiol 458:487–499, 1992.

1035. Plomp JJ, Van Kempen GT, De Baets MB, et al: Acetylcholine release in myasthenia gravis: Regulation at single end-plate level. Ann Neurol 37:627–636, 1995.

1036. Lambert EH, Eaton LM, Rooke ED: Defect of neuromuscular conduction associated with malignant neoplasm. Am J Physiol 187:612–613, 1956.

1037. Takamori M, Maruta T, Komai K: Lambert-Eaton myasthenic syndrome as an autoimmune calcium-channelopathy. Neurosci Res 36:183–191, 2000.

1038. Leveque C, Hoshino T, David P, et al: The synaptic vesicle protein synaptotagmin associates with calcium channels and is a putative Lambert-Eaton myasthenic syndrome antigen. Proc Natl Acad Sci U S A 89:3625–3629, 1992.

1039. Sudhof TC: The synaptic vesicle cycle: A cascade of protein-protein interactions. Nature 375:645–653, 1995.

1040. Hewett SJ, Atchison WD: Serum and plasma from patients with Lambert-Eaton myasthenic syndrome reduce depolarization-dependent uptake of ⁴⁵ Ca²⁺ into rat cortical synaptosomes. Brain Res 566:320–324, 1991.

1041. Sanders DB: Lambert-Eaton myasthenic syndrome: Clinical diagnosis, immune-mediated mechanisms, and update on therapies. Ann Neurol 37(Suppl 1):S63–S73, 1995.

1042. Sanders DB, Massey JM, Sanders LL, et al: A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 54:603–607, 2000.

1043. Engel AG, Ohno K, Milone M, et al: Congenital myasthenic syndromes. New insights from molecular genetic and patch-clamp studies. Ann N Y Acad Sci 841:140–156, 1998.

1044. Engel AG, Ohno K, Sine SM: Congenital myasthenic syndromes: Recent advances. Arch Neurol 56:163–167, 1999.

1045. Engel AG, Ohno K, Sine SM: Congenital myasthenic syndromes: Progress over the past decade. Muscle Nerve 27:4–25, 2003.

1046. Engel AG, Walls TJ, Nagel A, et al: Newly recognized cogenital myasthenic syndromes: I. Congenital paucity of synaptic vesicles and reduced quantal release. II. High-conductance fast-channel syndrome. III. Abnormal acetylcholine receptor (AChR) interaction with acetylcholine. IV. AChR deficiency and short channel-open time. Prog Brain Res 84:125–137, 1990.

1047. Engel AG, Lambert EH, Gomez MR: A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release. Ann Neurol 1:315–330, 1977.

1048. Ohno K, Tsujino A, Brengman JM, et al: Choline acetyl-transferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc Natl Acad Sci U S A 98:2017–2022, 2001.

1049. Ohno K, Engel AG, Shen XM, et al: Rapsyn mutations in humans cause endplate acetylcholine-receptor deficiency and myasthenic syndrome. Am J Hum Genet 70:875–885, 2002.

1050. Jeyarasasingam G, Yeluashvili M, Quik M: Nitric oxide is involved in acetylcholinesterase inhibitor-induced myopathy in rats. J Pharmacol Exp Ther 295:314–320, 2000.